3 Potentially Explosive Stocks You'll Want in Your Portfolio Before the Next Bull Market (and They're Dirt Cheap Now)The Motley Fool • 10/20/22
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Authorization Of Moderna's Omicron BA.4-BA.5 Targeting Bivalent Covid-19 Vaccine In The European UnionAccesswire • 10/19/22
EMA Committee for Medicinal Products for Human Use Issues Positive Opinion Recommending Authorization for the Use of Spikevax (mRNA-1273) in Children 6 Months - 5 Years in the European UnionAccesswire • 10/19/22
Moderna Stock Fails At Declining 50-Day Average; Check Out This Bearish Option PlayInvestors Business Daily • 10/19/22
90-Day Analysis Shows Moderna's Omicron BA.1-Targeting Bivalent Vaccine, mRNA-1273.214, Demonstrates Superior Antibody Response as Fourth Booster Compared to Spikevax Prototype BoosterAccesswire • 10/19/22
Moderna, Gavi cancel COVID-19 vaccine orders for rest of 2022 due to 'sufficient supply'Market Watch • 10/17/22
Moderna Announces Update to 2022 Supply Agreement with Gavi that Secures Access to Updated Variant-Specific COVID-19 Vaccines for Low-and-Middle Income CountriesAccesswire • 10/17/22